REV-ERBα integrates colon clock with experimental colitis through regulation of NF-κB/NLRP3 axis

  • Nat Commun. 2018 Oct 12;9(1):4246. doi: 10.1038/s41467-018-06568-5.
Shuai Wang  1  2 Yanke Lin  1 Xue Yuan  1 Feng Li  3 Lianxia Guo  1 Baojian Wu  4  5
Affiliations
  • 1. Reserach Center for Biopharmaceutics and Pharmacokinetics, College of Pharmacy, Jinan University, Guangzhou, 510632, China.
  • 2. Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research, Jinan University, Guangzhou, 510632, China.
  • 3. Guangzhou Jinan Biomedicine Research and Development Center, Jinan University, Guangzhou, 510632, China.
  • 4. Reserach Center for Biopharmaceutics and Pharmacokinetics, College of Pharmacy, Jinan University, Guangzhou, 510632, China. [email protected].
  • 5. Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research, Jinan University, Guangzhou, 510632, China. [email protected].
Abstract

The roles of Rev-erbα and circadian clock in colonic inflammation remain unclarified. Here we show colon clock genes (including Rev-erbα) are dysregulated in mice with DSS-induced colitis. In turn, disruption of the circadian clock exacerbates experimental colitis. Rev-erbα-deficient mice are more sensitive to DSS-induced colitis, supporting a critical role of Rev-erbα in disease development. Further, Rev-erbα ablation causes activation of NLRP3 inflammasome in mice. Cell-based experiments reveal Rev-erbα inactivates NLRP3 inflammasome mainly at the priming stage. Rev-erbα directly represses NLRP3 transcription through specific binding to the promoter region. Additionally, Rev-erbα represses p65 transcription and indirectly repressed NLRP3 via the NF-κB pathway. Interestingly, Rev-erbα activation in wild-type mice by SR9009 attenuates DSS-induced colitis, whereas the protective effects are lost in NLRP3-/- and Rev-erbα-/- mice. Taken together, Rev-erbα regulates experimental colitis through its repressive action on the NF-κB/NLRP3 axis. Targeting Rev-erbα may represent a promising approach for prevention and management of colitis.

Products